109 related articles for article (PubMed ID: 9159340)
1. Is OVX1 a suitable marker for endometrial cancer?
Beck EP; Wagner M; Anselmino L; Xu F; Bast RC; Jaeger W
Gynecol Oncol; 1997 May; 65(2):291-6. PubMed ID: 9159340
[TBL] [Abstract][Full Text] [Related]
2. OVX1 as a marker for early stage endometrial carcinoma.
Xu FJ; Yu YH; Daly L; Anselmino L; Hass GM; Berchuck A; Rodriguez GC; Soper JT; Clarke-Pearson DL; Hollis D
Cancer; 1994 Apr; 73(7):1855-8. PubMed ID: 8137210
[TBL] [Abstract][Full Text] [Related]
3. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
4. OVX1 and CEA in patients with colon carcinoma, colon polyps and benign colon disorders.
Martell RE; Xu FJ; Davis WZ; Anselmino L; Yu YH; Daly L; Bast RC
Int J Biol Markers; 1998; 13(3):145-9. PubMed ID: 10079388
[TBL] [Abstract][Full Text] [Related]
5. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
van Haaften-Day C; Shen Y; Xu F; Yu Y; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Bast RC; Hacker NF
Cancer; 2001 Dec; 92(11):2837-44. PubMed ID: 11753957
[TBL] [Abstract][Full Text] [Related]
6. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
7. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass.
Hogdall EV; Høgdall CK; Tingulstad S; Hagen B; Nustad K; Xu FJ; Bast RC; Jacobs IJ
Int J Cancer; 2000 Nov; 89(6):519-23. PubMed ID: 11102897
[TBL] [Abstract][Full Text] [Related]
8. The utility of serum CA-125 in predicting extra-uterine disease in apparent early-stage endometrial cancer.
Nicklin J; Janda M; Gebski V; Jobling T; Land R; Manolitsas T; McCartney A; Nascimento M; Perrin L; Baker JF; Obermair A;
Int J Cancer; 2012 Aug; 131(4):885-90. PubMed ID: 21918977
[TBL] [Abstract][Full Text] [Related]
9. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies.
Suzuki M; Ohwada M; Sato I; Nagatomo M
Oncology; 1995; 52(2):128-33. PubMed ID: 7854772
[TBL] [Abstract][Full Text] [Related]
10. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
[TBL] [Abstract][Full Text] [Related]
11. OVX1 radioimmunoassay results are dependent on the method of sample collection and storage.
Hogdall EV; Hogdall CK; Kjaer SK; Xu F; Yu Y; Bast RC; Blaakaer J; Jacobs IJ
Clin Chem; 1999 May; 45(5):692-4. PubMed ID: 10222361
[No Abstract] [Full Text] [Related]
12. Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data.
Ferdeghini M; Gadducci A; Prontera C; Marrai R; Malagnino G; Annicchiarico C; Fioretti P; Bianchi R
Anticancer Res; 1993; 13(3):709-13. PubMed ID: 8317901
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of squamous cell carcinoma antigen in cancer of the human uterine cervix. Comparison with CEA and CA-125.
Verlooy H; Devos P; Janssens J; Mortelmans L; Gerits M; Bonte J; De Roo M
Gynecol Obstet Invest; 1991; 32(1):55-8. PubMed ID: 1765320
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma.
Avall-Lundqvist EH; Sjövall K; Nilsson BR; Eneroth PH
Eur J Cancer; 1992; 28A(10):1695-702. PubMed ID: 1389488
[TBL] [Abstract][Full Text] [Related]
15. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
16. Preoperative CA 125 tumour marker in endometrial cancer: correlation with advanced stage disease.
Sebastianelli A; Renaud MC; Grégoire J; Roy M; Plante M
J Obstet Gynaecol Can; 2010 Sep; 32(9):856-860. PubMed ID: 21050518
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix.
Takeda M; Sakuragi N; Okamoto K; Todo Y; Minobe S; Nomura E; Negishi H; Oikawa M; Yamamoto R; Fujimoto S
Acta Obstet Gynecol Scand; 2002 May; 81(5):451-7. PubMed ID: 12027820
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
[TBL] [Abstract][Full Text] [Related]
19. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
20. Circulating CA 549 and other associated antigens in breast cancer patients.
Pavesi F; Lotzniker M; Scarabelli M; Mauro E; Visconti G; Nicolato E; Moratti R
Oncology; 1994; 51(1):18-21. PubMed ID: 8265097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]